Showing 2281-2290 of 7668 results for "".
- VisualDx, Vaseline Join Forces to Advance Education on Treating Skin of Colorhttps://practicaldermatology.com/news/visualdx-vaseline-join-forces-to-advance-education-on-treating-skin-of-color/2461817/VisualDx and Vaseline are partnering to improve health equity by enhancing provider education on skin of color. This announcement comes after the organizations' collaboration last year to create See My Skin, the only database designed to search for conditions on skin of color and offer a tool to…
- Welcome to Camp Dermhttps://practicaldermatology.com/news/welcome-to-camp-derm/2461816/As kids across the country got ready for summer camp, dermatologists flocked to Brooklyn, NY for their own version of summer camp: Neutrogena’s immersive SkinU Summer Camp. Instead of learning to swim, sliding down a zipline, or playing tennis like kids in camp often do, these dermatologists learn…
- In With the Old: Curettage and Cryosurgery Still Effective for BCChttps://practicaldermatology.com/news/in-with-the-old-curettage-and-cryosurgery-still-effective-for-bcc/2461815/The combination of curettage and cryosurgery is a safe and effective treatment method for basal cell carcinoma, and now, a new study presents the results from testing different variants of the method. The current study, which appears in the Journal of the American Academy of Dermatology, applied a…
- US FDA Nod for Pfizer's Alopecia Drughttps://practicaldermatology.com/news/us-fda-nod-for-pfizers-alopecia-drug/2461814/The US Food and Drug Administration (FDA) approved Litfulo (ritlecitinib, Pfizer Inc) for severe alopecia areata in individuals 12 years of age and older. A kinase inhibitor that targets Janus kinase 3 (JAK3) and the tyrosine kinase expressed in the hepatocellular carcinoma (TEC) family of kinases…
- Bimekizumab Update: FDA Still Reviewing UCB's BLAhttps://practicaldermatology.com/news/bimekizumab-update-fda-still-reviewing-ucbs-bla/2461813/The U.S. Food & Drug Administration (FDA) is still reviewing UCB’s Biologics License Application (BLA) for bimekizumab for moderate to severe plaque psoriasis, UCB reports. UCB previously communicated the FDA action was expected in Q2 2023. UCB now anticipates the FDA action in Q3 2023. There are …
- HS Pipeline Update: HS Patients Taking Nanobody Sonelokimab Hit HiSCR 75 as Early as Week 12https://practicaldermatology.com/news/hs-pipeline-update-hs-patients-taking-nanobody-sonelokimab-hit-hiscr-75-as-early-as-week-12/2461806/Nanobody Sonelokimab is looking good in patients with moderate-to-severe hidradenitis suppurativa (HS), according to topline Phase 2 results from MoonLake Immunotherapeutics. Nanobodies are antibody-derived targeted therapies. They consist of one or more domains based on the small antigen-binding …
- Biosimilar News: Optum Rx Lists Cyltezo on Formularyhttps://practicaldermatology.com/news/biosimilar-news-optum-rx-lists-cyltezo-on-formulary/2461805/Optum Rx, a pharmacy benefit manager and subsidiary of UnitedHealth Group, will place Cyltezo (adalimumab-adbm) on its commercial formulary as a preferred brand, Boehringer Ingelheim reports. Cyltezo is a US Food and Drug Administration (FDA)-approved Interchangeable biosimilar to Humira (adalimum…
- DataDerm in Action: AAD Launches Project to Improve Outcomes for GPP Patientshttps://practicaldermatology.com/news/aad-launches-project-to-improve-outcomes-for-gpp-patients/2461804/The American Academy of Dermatology is launching a new project to develop educational resources to improve the evaluation, diagnosis, and treatment of patients with generalized pustular psoriasis (GPP). The AAD is working with Boehringer Ingelheim and using OM1’s data aggregation system and its Ph…
- Paradigm Shift: Can Harnessing the Power of Healthy Cells Prevent Skin Cancer?https://practicaldermatology.com/news/paradigm-switch-can-harnessing-the-power-of-healthy-cells-prevent-skin-cancer/2461803/Do simple wounds or surgery increase skin cancer risks by expanding mutated cells? No, according to a new study by researchers at Yale and the Karolinska Institute in Sweden. Rather than promoting mutant cell growth, injury promotes healthy-cell expansion which keeps mutated cell growth under cont…
- Osteopontin Potently Stimulates Hair Follicle Stem Cells for Robust Hair Growthhttps://practicaldermatology.com/news/osteopontin-potently-stimulates-hair-follicle-stem-cells-for-robust-hair-growth/2461802/Do hairy moles hold the secret to understanding hair growth? Maybe, according to research published in the June 21, 2023 issue of Nature. Using a mouse model, researchers tracked the activity of hair follicle stem cells in mole skin over time and found that the excessive hair growth in these mice …